ArticleAdvances in hematology2022

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.

Mario Petrini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.